Eshelman Innovation

What Eshelman Innovation does

Eshelman Innovation is a university-affiliated non-profit innovation engine operating within the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. Founded in 2013 (rebranded 2021), the organization runs two principal programs: the Therapeutics Accelerator, which provides strategic funding, regulatory guidance, and project management to advance novel drug candidates in oncology, neuroscience, infectious disease, and autoimmune disorders through preclinical and early development — deploying more than $30M in therapeutic grants and helping raise nearly $100M for the READDI antiviral initiative — and the Venture Studio, which uses structured 13-week sprint programs to conceive, de-risk, and launch digital health startups with approximately $1M in pre-seed capital per concept. Its core technology platform, Kairos (launched October 2025 in partnership with AWS), integrates agentic AI and generative AI tools across the venture creation workflow, complementing the Therapeutics Accelerator's access to a state-of-the-art CRISPR Genetic & Epigenetic Screening Center and DNA-Encoded Library screening via a partnership with HitGen.

The organization serves a heterogeneous stakeholder base rather than commercial customers: UNC faculty researchers developing therapeutic discoveries, health systems (Atrium Health, UNC Health, MAHEC) co-developing digital health ventures, biopharma partners (Orange Grove Bio, HitGen), federal and state funders (NIH/NIAID, NC Collaboratory, NC Biotech Center), philanthropic donors (Humana Foundation), and technology partners (AWS, High Alpha Innovation, Alloy Partners). Its business model is grant-mediated rather than revenue-generating: funding flows from federal grants, state appropriations, philanthropic gifts, and equity stakes in portfolio companies (Goldie, Valable, Kudo Health, TerraLink, Kairos). Portfolio outcomes include Goldie progressing to Series A for overdose prevention, Dr. Greg Scherrer's pain therapeutic research leveraging Eshelman funding into a $12M NIH grant, and the FDA Triangle CERSI regulatory science collaboration. The organization maintains offices in Chapel Hill (headquarters), Charlotte, Durham, and Asheville, with an Aston University international research partnership extending its footprint to the UK.

Name

Eshelman Innovation

Legal name

Eshelman Innovation

Website

https://eshelmaninnovation.org

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Eshelman Innovation is a UNC Eshelman School of Pharmacy non-profit that funds novel therapeutics and builds digital health startups through its Therapeutics Accelerator and Venture Studio (including the Kairos AI platform), serving academic researchers, health systems, biopharma, and government funders.

Ownership category

akta.pro rank

Product category

Healthcare Innovation and Translational Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Management Consulting Services (8742), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAIACAA

Oncology Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Healthcare innovation acceleration
• Venture studio services
• Therapeutics translational research
• Academic commercialization support
• Digital health venture building

Headquarters

HQ city

Chapel Hill , North Carolina

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Therapeutic Grants and Funding: Strategic funding deployed toward novel therapeutics in oncology, neuroscience, and infectious disease through grant programs including the Innovation Curation Program, Rankin Innovator Awards, and Autoimmune Disease Grants. Total therapeutic funding exceeds $30 million.
2. Venture Studio Investment Returns: The Venture Studio creates and invests in digital health startup companies, providing pre-seed capital (approximately $1M per concept) and receiving equity stakes in return. Returns realized upon subsequent funding rounds or exits.
3. State and Federal Funding: Funding from NC Collaboratory (state appropriations), NIH grants (e.g., $65M NIAID AViDD grant for READDI), and other government sources to support translational research and pandemic preparedness initiatives.
4. Philanthropic Donations: Generous donor support including $2M anonymous gift to Drug Discovery Initiative and grants from foundations supporting specific initiatives like the Humana Foundation funding for PowerUp ($750,000).

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Eshelman Innovation operates as an innovation engine within the UNC Eshelman School of Pharmacy that advances healthcare therapeutics and digital health ventures from discovery to commercialization. It runs two core programs: a Therapeutics Accelerator that funds and de-risks novel therapeutics in oncology, neuroscience, infectious disease, and autoimmune disorders, and a Venture Studio that runs structured 13-week sprints to conceive, de-risk, and launch venture-backable digital health startup companies.

Product overview

Eshelman Innovation is an emerging innovation engine operating two main programs: the Therapeutics Accelerator for novel therapeutics in oncology, neuroscience, and infectious disease, and the Venture Studio for digital health startups. The portfolio includes portfolio companies READDI (broad-spectrum antivirals), Drug Discovery Initiative (CRISPR/DEL screening), Triangle CERSI (FDA regulatory science), Kairos (AI-powered venture studio), and startup brands Goldie (overdose prevention), Kudo Health (rural pharmacy services), Valable (recovery workplace platform), and TerraLink (food insecurity). The organization moves healthcare ideas from discovery through commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• Therapeutics Accelerator: Strategic funding and translational initiatives that de-risk cutting-edge innovations and move assets from discovery to preclinical and early development studies, focused on oncology, neuroscience, and infectious disease
• Venture Studio
• Kairos
• READDI
• Drug Discovery Initiative (DDI)
• Triangle CERSI
• Goldie
• Valable
• Kudo Health
• TerraLink

Products and services

• Therapeutics Accelerator
• Venture Studio
• Drug Discovery Initiative (DDI)
• Kairos AI Venture Creation Platform

Quantifiable outcome

• $65M NIH NIAID AViDD grant secured for READDI antiviral drug development
• +4 more outcomes

Named customers10 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

18 partnerships are on record, tiered core, major and minor.

• Amazon Web Services (AWS)coreTechnology or Integration · 1 January 2025AWS provides foundational cloud and AI partnership for Kairos venture studio. Venture teams receive free access to cloud infrastructure, AI/ML services, technical mentorship, startup credits, and CTO-in-residence services. AWS experts provide training and standard business agreements with UNC.
• High Alpha InnovationcoreStrategic or Co-development Partner · 1 January 2021Leading venture builder headquartered in Indianapolis partnering with Eshelman Innovation on the Digital Health Venture Studio to create digital health startups. Provided initial pilot program with 25 digital health concepts.
• Alloy PartnerscoreStrategic or Co-development PartnerVenture building partner collaborating on Digital Health Venture Studio sprints including opioid epidemic programs in Asheville, NC. Conducts gate review panels and supports concept evaluation.
• Orange Grove BiocoreStrategic or Co-development PartnerBiopharmaceutical company-creation firm partnering with university researchers to develop and commercialize transformative therapies. Co-sponsored Eshelman Innovation autoimmune summit in 2025 and provides investment thesis alignment for identifying promising science.
• FDA Triangle CERSIcoreStrategic or Co-development PartnerFDA awarded $50M to UNC and Duke to establish Research Triangle Center of Excellence in Regulatory Science and Innovation (CERSI), also involving NC State and NC Central University. Accelerates FDA response to complex challenges including opioid epidemic.
• Mountain Area Health Education Center (MAHEC)coreStrategic or Co-development PartnerPartner in Asheville opioid epidemic sprints and collaborative practice agreement development for Kudo Health. Provides clinical expertise and community connections for addressing substance use disorders.
• HitGenmajorTechnology or IntegrationPremier DNA-Encoded Library company providing UNC researchers no-cost access to screening technology in exchange for sharing resulting intellectual property. Enables rapid screening of billions of compounds.
• Alexandria Real EstatemajorStrategic or Co-development PartnerReal estate partner co-hosting the Shaping the Future of Autoimmune Therapies Summit at Apella RT facility in Durham, NC. Supports innovation event infrastructure.
• HBCU Founders InitiativemajorGTM or Marketing PartnerPartnership to serve underrepresented populations and source innovations from HBCU students. Co-sponsors entrepreneurial workshops and pitch competitions addressing health equity challenges in Black communities.
• Aston UniversityminorStrategic or Co-development PartnerThree-year research collaboration focused on preventing damage caused by swelling of the central nervous system (CNS). Part of international research partnership to advance novel treatments.
• North Carolina Central UniversitymajorStrategic or Co-development PartnerHBCU partner for addressing food insecurity and behavioral health through the Venture Studio. Leverages deep faculty domain expertise to identify compelling problems and apply venture studio model for digital health ventures.
• UNC Eshelman School of PharmacycoreStrategic or Co-development PartnerParent organization and primary host institution. Eshelman Innovation operates within the school and leverages its faculty, facilities, and research infrastructure.
• UNC School of MedicinecoreStrategic or Co-development PartnerKey research partner for therapeutics development. Houses researchers like Dr. Greg Scherrer and Dr. Andrew Satterlee whose work is supported by Eshelman Innovation.
• UNC Lineberger Comprehensive Cancer CentercoreStrategic or Co-development PartnerUNC's NCI-designated comprehensive cancer center partnering on Drug Discovery Initiative and CRISPR screening facility. Provides research infrastructure and expertise for cancer therapeutics development.
• Atrium HealthcoreStrategic or Co-development PartnerMajor health system partner for Kairos venture studio sprints in Charlotte, NC. Provides clinical expertise, patient populations, and entrepreneurial opportunities for digital health ventures.
• UNC HealthcoreStrategic or Co-development PartnerAcademic health system partner for venture studio sprints, providing digital health innovation opportunities and clinical collaboration pathways.
• Duke UniversitycoreStrategic or Co-development PartnerPartner in FDA Triangle CERSI center and research collaborations. Brings complementary expertise to regulatory science and innovation initiatives.
• NC State UniversityminorStrategic or Co-development PartnerPartner in Triangle CERSI initiative bringing additional research capabilities to regulatory science collaboration.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• MBC BioLab: MBC BioLab is the largest biotech co-working incubator in the San Francisco Bay Area, providing lab space and resources to hundreds of early-stage life science startups. Comparable as a life science startup incubator model, though focused on physical lab infrastructure rather than therapeutics funding.
• Petri: Petri is an early-stage biotech accelerator based in Boston that supports founders building transformative biotechnology companies. Comparable as a biotech venture creation platform with similar emphasis on converting scientific innovation into funded companies.
• University City Science Center: University City Science Center is a Philadelphia-based innovation hub that connects university research with startup creation and corporate partners. Comparable as a regional university research-to-startup conversion platform with similar mission of translating academic discoveries into commercial ventures.
• IndieBio: IndieBio is a biotech accelerator that funds and builds early-stage science-driven startups across therapeutics, diagnostics, and bioindustrials. Comparable as a venture builder focused on translating deep science into companies, though IndieBio operates as a for-profit accelerator independent of a single university.
• BioGenerator: BioGenerator is a St. Louis-based startup generator that creates and invests in biotech companies emerging from regional academic research institutions. Closely comparable to Eshelman Innovation as a regional academic-to-venture generator with therapeutic and startup-building capabilities.

Broad incumbents

• Flagship Pioneering: Flagship Pioneering is a Cambridge-based bioplatform innovation company that conceives, creates, and funds biotech companies from novel scientific concepts. Comparable to Eshelman Innovation's model of converting research into venture-backable therapeutic and platform companies, though Flagship operates at significantly larger scale across multiple disease areas globally.
• JLABS (Johnson & Johnson Innovation): JLABS is a global network of life science incubators operated by Johnson & Johnson Innovation, providing capital-efficient lab space and resources to early-stage healthcare startups. Comparable as a healthcare-focused incubator model, though JLABS operates at much larger global scale under a large pharmaceutical sponsor.
• ARCH Venture Partners: ARCH Venture Partners is a leading early-stage venture firm that invests in and builds biotechnology, advanced materials, and other deep technology companies from academic and corporate research sources. Comparable as a venture builder for science-driven companies, with substantially larger fund sizes.
• Alexandria LaunchLabs: Alexandria LaunchLabs is a life science startup platform that provides capital, lab space, and strategic support to early-stage companies. Comparable as an incubator providing infrastructure and capital to emerging life science ventures, though part of a larger real estate platform.
• Y Combinator: Y Combinator is a leading global startup accelerator that funds and mentors early-stage companies across industries. Comparable as a structured venture-building sprint model, though Y Combinator is industry-agnostic and operates at vastly larger scale without a therapeutic research focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eshelman-innovation

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eshelman Innovation